Drug intelligence / Profile preview

IAX30-Series

Development stage: Preclinical
Lead developer: InterAx Biotech
Modality: Small Molecules
Administration: Oral

Overview

The IAX30-Series is a preclinical-stage, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by InterAx Biotech for the treatment of obesity and type 2 diabetes. Discovered using the company's proprietary Deep Signal™ discovery platform, which combines computational pharmacology with experimental methods, the IAX30-Series is designed to achieve a superior signaling profile. The program aims to provide high efficacy in weight loss and glycemic control while addressing common tolerability issues associated with GLP-1 therapies, specifically targeting a reduction in gastrointestinal side effects like nausea and vomiting. It is intended for once-daily oral administration.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on IAX30-Series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAX30-Series.

Explore the full profile